Healthcare providers, such as doctors and pharmacists, often refer to AFINITOR as everolimus. This is just the generic name for the same medicine.
Everolimus is part of a class of drugs called mTOR (mammalian target of rapamycin) inhibitors. It may slow the growth and spread of kidney cancer and pancreatic neuroendocrine tumors, and may reduce the size of SEGA brain tumors that are seen with tuberous sclerosis complex (TSC).1
What does AFINITOR treat?
AFINITOR® (everolimus) is Food and Drug Administration (FDA)-approved to treat:
- Advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have already received certain other medicines for their cancer
Find out more about everolimus in the treatment of advanced HR+, HER2- negative BC - Adults with a type of pancreatic cancer known as pancreatic neuroendocrine tumor (PNET) that has progressed and cannot be treated with surgery. It is not known if AFINITOR is safe and effective in people with carcinoid tumors
Find out more about everolimus in the treatment of advanced PNET - Adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines have not worked
Find out more about everolimus in the treatment of advanced RCC - Adults with a kidney tumor called angiomyolipoma, seen with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require surgery right away
- The effectiveness of AFINITOR in treating angiomyolipoma of the kidney is based on a study of patients treated over an average of 8.3 months. More information is needed to understand the long-term effects of treatment with AFINITOR
- Adults and children with a genetic condition called tuberous sclerosis complex (TSC) who have a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed completely by surgery
- The effectiveness of AFINITOR is based on change in SEGA size. Improvement in disease-related symptoms or overall survival has not been shown
Reference
1. AFINITOR [prescribing information]. East Hanover, NJ; Novartis Pharmaceuticals Corp; August 2012.
Important Safety Information
AFINITOR can cause serious side effects, including lung or breathing problems, infections, and kidney failure, which can lead to death. Mouth ulcers and mouth sores are common side effects, occurring in up to 86% of patients taking AFINITOR. AFINITOR can affect blood cell counts, kidney and liver function, and blood sugar and cholesterol levels. Regular blood tests should be performed before starting AFINITOR and as needed during treatment to check blood cell count, kidney and liver function, and blood sugar and cholesterol levels. For SEGA patients, blood tests to see how much AFINITOR is in the blood should also be performed.
Please see additional Important Safety Information.
AFINITOR is a prescription medicine used to treat:
- Advanced hormone receptor-positive, HER2-negative breast cancer, along with the medicine exemestane, in postmenopausal women who have already received certain other medicines for their cancer
- Adults with a type of pancreatic cancer known as pancreatic neuroendocrine tumor (PNET) that has progressed and cannot be treated with surgery. It is not known if AFINITOR is safe and effective in people with carcinoid tumors
- Adults with advanced kidney cancer (renal cell carcinoma or RCC) when certain other medicines have not worked
- Adults with a kidney tumor called angiomyolipoma, seen with a genetic condition called tuberous sclerosis complex (TSC), when their kidney tumor does not require surgery right away
- The effectiveness of AFINITOR in treating angiomyolipoma of the kidney is based on a study of patients treated over an average of 8.3 months. More information is needed to understand the long-term effects of treatment with AFINITOR
- Adults and children with a genetic condition called tuberous sclerosis complex (TSC) who have a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed completely by surgery
- The effectiveness of AFINITOR is based on change in SEGA size. Improvement in disease-related symptoms or overall survival has not been shown
AFINITOR DISPERZ is a prescription medicine used to treat adults and children with a genetic condition called tuberous sclerosis complex (TSC) who have a brain tumor called subependymal giant cell astrocytoma (SEGA) when the tumor cannot be removed completely by surgery.
- The effectiveness of AFINITOR is based on change in SEGA size. Improvement in disease-related symptoms or overall survival has not been shown
